Pfizer : FDA Approves Talzenna-Xtandi Combination To Treat Prostate Cancer
Pfizer (PFE) said that the U.S. Food and Drug Administration has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with homologous recombination repair or HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).